Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis facto...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Schoot, Lara S., van den Reek, Juul M. P. A., Grine, Lynda, Schots, Lisa, Kievit, Wietske, Lambert, Jo L. W., de Jong, Elke M. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520290/
https://www.ncbi.nlm.nih.gov/pubmed/34656148
http://dx.doi.org/10.1186/s13063-021-05681-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520290/
https://www.ncbi.nlm.nih.gov/pubmed/34656148
http://dx.doi.org/10.1186/s13063-021-05681-z

Ejemplares similares